RxDoctor Payments Data

Karl Undesser, MD

Clinical Cardiac Electrophysiology · Caldwell, IDNPI 1013961242

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,904 of the $8,638 with a category attached, or 79.9%. 21 manufacturers reported payments, led by Medtronic at 37.3% of the total. 2025 is the largest year on record at $3,589, 7.7 times the $469 reported in 2019.

$8,638in general payments, 2019–2025

Across 192 payments — averaging $44.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Abbott$1K
  • Boston Scientific$713
  • Atricure, Inc.$546
  • Novartis$235
  • plus $1K from 15 others

What the payments were for

  • Consulting fees$2503%
  • Travel & lodging$1,48417%
  • Food & beverage$6,90480%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$233,891
Medicare patients
764
Services billed
2,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,125$1,294,419
XareltoRivaroxaban139$182,080
EntrestoSacubitril/Valsartan29$48,457
FarxigaDapagliflozin Propanediol20$24,951
SotalolSotalol Hcl515$15,431
Flecainide Acetate208$8,783
CorlanorIvabradine Hcl16$8,748
Metoprolol Succinate528$8,541
Acebutolol Hcl112$7,915
Praluent PenAlirocumab15$7,589
Bisoprolol Fumarate176$4,840
Losartan Potassium386$3,869
Digoxin104$2,910
Diltiazem 24hr Er (Cd)Diltiazem Hcl65$2,762
Amiodarone Hcl176$2,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$131$1,294,4191,125 claims
Johnson & JohnsonXarelto$89$182,080139 claims
NovartisEntresto$235$48,45729 claims
AstraZenecaFarxiga$63$24,95120 claims
AmgenCorlanor$34$8,74816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in Idahoon file to place this against a meaningful peer group, so we don't.

Other clinical cardiac electrophysiology in Caldwell

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →